Transformation by E1A oncoprotein involves ubiquitin-mediated proteolysis of the neuronal and tumor repressor REST in the nucleus

Journal of Virology

Volumn 86, Issue 10, 2012, Pages 5594-5602

  Guan, Hancheng ^a   Ricciardi, Robert P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E1A PROTEIN; MYC PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR REST; UNCLASSIFIED DRUG;

ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; MUTATION; NERVE CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; UBIQUITINATION; UPREGULATION; VIRUS TRANSFORMATION;

ADENOVIRUS E1A PROTEINS; ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ANIMALS; CELL NUCLEUS; CELL TRANSFORMATION, VIRAL; HELA CELLS; HUMANS; MICE; NEURONS; NIH 3T3 CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; REPRESSOR PROTEINS; UBIQUITIN; UBIQUITINATION;

ADENOVIRIDAE; RODENTIA;

EID: 84861310000     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06811-11     Document Type: Article

References (56)

1. Albert ML, Darnell RB. 2004. Paraneoplastic neurological degenerations: keys to tumour immunity. Nat. Rev. Cancer 4:36-44.
2. Bader N, Jung T, Grune T. 2007. The proteasome and its role in nuclear protein maintenance. Exp. Gerontol. 42:864-870.
3. Blanchette P, Branton PE. 2009. Manipulation of the ubiquitinproteasome pathway by small DNA tumor viruses. Virology 384:317-323.
4. Boyd SD, Tsai KY, Jacks T. 2000. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2:563-568.
5. Carvalho T, et al. 1995. Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J. Cell Biol. 131:45-56.
6. Chen W, Böcker W, Brosius J, Tiedge H. 1997. Expression of neural BC200 RNA in human tumours. J. Pathol. 183:345-351.
7. Chen Y, Dai X, Haas AL, Wen R, Wang D. 2006. Proteasome-dependent down-regulation of activated Stat5A in the nucleus. Blood 108:566 -574.
8. Chong JA, et al. 1995. REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 80:949 -957.
9. Coulson JM. 2005. Transcriptional regulation: cancer, neurons and the REST. Curr. Biol. 15:R665-R668.
10. Ferrari R, et al. 2008. Epigenetic reprogramming by adenovirus e1a. Science 321:1086 -1088.
11. Finley D. 2009. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem. 78:477-513.
12. Floyd ZE, Trausch-Azar JS, Reinstein E, Ciechanover A, Schwartz AL. 2001. The nuclear ubiquitin-proteasome system degrades MyoD. J. Biol. Chem. 276:22468 -22475.
13. Frescas D, Pagano M. 2008. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat. Rev. Cancer 8:438-449.
14. Fuchs SY, Spiegelman VS, Kumar KG. 2004. The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 23:2028 -2036.
15. Garber ME, et al. 2001. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl. Acad. Sci. U. S. A. 98:13784 -13789.
16. Garrenton LS, et al. 2009. Nucleus-specific and cell cycle-regulated degradation of mitogen-activated protein kinase scaffold protein Ste5 contributes to the control of signaling competence. Mol. Cell. Biol. 29:582- 601.
17. Gillies SG, et al. 2011. Distinct gene expression profiles directed by the isoforms of the transcription factor neuron-restrictive silencer factor in human SK-N-AS neuroblastoma cells. J. Mol. Neurosci. 44:77-90.
18. Gopalakrishnan V. 2009. REST and the RESTless: in stem cells and beyond. Future Neurol. 4:317-329.
19. Gröne J, et al. 2006. Robo1/Robo4: differential expression of angiogenic markers in colorectal cancer. Oncol. Rep. 15:1437-1443.
20. Guan H, Hou S, Ricciardi RP. 2005. DNA binding of repressor nuclear factor-kappaB p50/p50 depends on phosphorylation of Ser337 by the protein kinase A catalytic subunit. J. Biol. Chem. 280:9957-9962.
21. Guan H, Jiao J, Ricciardi RP. 2008. Tumorigenic adenovirus type 12 E1A inhibits phosphorylation of NF-kappaB by PKAc, causing loss of DNA binding and transactivation. J. Virol. 82:40-48.
22. Guan H, Williams JF, Ricciardi RP. 2009. Induction of neuronal and tumor-related genes by adenovirus type 12 E1A. J. Virol. 83:651- 661.
23. Guardavaccaro D, et al. 2008. Control of chromosome stability by the beta-TrCP-REST-Mad2 axis. Nature 452:365-369.
24. Hateboer G, et al. 1996. mUBC9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect. J. Biol. Chem. 271: 25906-25911.
25. Isobe T, et al. 2009. Adenovirus E1A inhibits SCF(Fbw7) ubiquitin ligase. J. Biol. Chem. 284:27766 -27779.
26. Jelinek T, Graham FL. 1992. Recombinant human adenoviruses containing hybrid adenovirus type 5 (Ad5)/Ad12 E1A genes: characterization of hybrid E1A proteins and analysis of transforming activity and host range. J. Virol. 66:4117- 4125.
27. Jelinek T, Pereira DS, Graham FL. 1994. Tumorigenicity of adenovirustransformed rodent cells is influenced by at least two regions of adenovirus type 12 early region 1A. J. Virol. 68:888-896.
28. Kallunki P, Edelman GM, Jones FS. 1997. Tissue-specific expression of the L1 cell adhesion molecule is modulated by the neural restrictive silencer element. J. Cell Biol. 138:1343-1354.
29. Kim CS, et al. 2008. Novel function of neuron-restrictive silencer factor (NRSF) for posttranscriptional regulation. Biochim. Biophys. Acta 1783: 1835-1846.
30. Kushner DB, Ricciardi RP. 1999. Reduced phosphorylation of p50 is responsible for diminished NF-kappaB binding to the major histocompatibility complex class I enhancer in adenovirus type 12-transformed cells. Mol. Cell. Biol. 19:2169 -2179.
31. Lafarga M, et al. 2002. Clastosome: a subtype of nuclear body enriched in 19S and 20S proteasomes, ubiquitin, and protein substrates of proteasome. Mol. Biol. Cell 13:2771-2782.
32. Lee JH, Shimojo M, Chai YG, Hersh LB. 2000. Studies on the interaction of REST4 with the cholinergic repressor element-1/neuron restrictive silencer element. Brain Res. Mol. Brain Res. 80:88 -98.
33. Lo RS, Massague J. 1999. Ubiquitin-dependent degradation of TGF-betaactivated smad2. Nat. Cell Biol. 1:472- 478.
34. Lunyak VV, Rosenfeld MG. 2005. No rest for REST: REST/NRSF regulation of neurogenesis. Cell 121:499 -501.
35. Majumder S. 2006. REST in good times and bad: roles in tumor suppressor and oncogenic activities. Cell Cycle 5:1929 -1935.
36. Nakajima T, et al. 1997. Induction of ubiquitin conjugating enzyme activity for degradation of topoisomerase II alpha during adenovirus E1Ainduced apoptosis. Biochem. Biophys. Res. Commun. 239:823- 829.
37. Palm K, Belluardo N, Metsis M, Timmusk T. 1998. Neuronal expression of zinc finger transcription factor REST/NRSF/XBR gene. J. Neurosci. 18:1280 -1296.
38. Pelka P, Ablack JN, Fonseca GJ, Yousef AF, Mymryk JS. 2008. Intrinsic structural disorder in adenovirus E1A: a viral molecular hub linking multiple diverse processes. J. Virol. 82:7252-7263.
39. Reddy BY, Greco SJ, Patel PS, Trzaska KA, Rameshwar P. 2009. RE-1-silencing transcription factor shows tumor-suppressor functions and negatively regulates the oncogenic TAC1 in breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 106:4408-4413.
40. Ricciardi R. 1995. Transformation and tumorigenesis mediated by the adenovirus E1A and E1B oncogenes, p 195-225. In Barbanti-Brodano G, Bendinelli M, Friedman H (ed), DNA tumor viruses: oncogenic mechanisms. Plenum Press, New York, NY.
41. Ricciardi RP. 1999. Adenovirus transformation and tumorigenicity, p 217-227. In Seth P (ed), Adenoviruses: from basic research to gene therapy applications. Landes Biosciences/Springer, New York, NY.
42. Ricciardi RP, Zhao B, Guan H. 2006. Mechanism of tumorigenesis mediated by adenovirus-12 E1A, p 107-124. In Tognon M (ed), Viral oncogenesis. Research Signpost, Kerala, India.
43. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17:554 -564.
44. Scharf A, Rockel TD, von Mikecz A. 2007. Localization of proteasomes and proteasomal proteolysis in the mammalian interphase cell nucleus by systematic application of immunocytochemistry. Histochem. Cell Biol. 127:591- 601.
45. Schrader EK, Harstad KG, Matouschek A. 2009. Targeting proteins for degradation. Nat. Chem. Biol. 5:815- 822.
46. Sears RC. 2004. The life cycle of C-myc: from synthesis to degradation. Cell Cycle 3:1133-1137.
47. Singh SK, Kagalwala MN, Parker-Thornburg J, Adams H, Majumder S. 2008. REST maintains self-renewal and pluripotency of embryonic stem cells. Nature 453:223-227.
48. Suizu F, et al. 2009. The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt. Dev. Cell 17:800-810.
49. Thompson SJ, Loftus LT, Ashley MD, Meller R. 2008. Ubiquitinproteasome system as a modulator of cell fate. Curr. Opin. Pharmacol. 8:90 -95.
50. Turnell AS, et al. 2000. Regulation of the 26S proteasome by adenovirus E1A. EMBO J. 19:4759-4773.
51. Wagoner MP, et al. 2010. The transcription factor REST is lost in aggressive breast cancer. PLoS Genet. 6:e1000979.
52. Westbrook TF, et al. 2008. SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 452: 370-374.
53. Westbrook TF, et al. 2005. A genetic screen for candidate tumor suppressors identifies REST. Cell 121:837- 848.
54. Williams JF, et al. 2004. E1A-based determinants of oncogenicity in human adenovirus groups A and C. Curr. Top. Microbiol. Immunol. 273: 245-288.
55. Zhang P, et al. 2008. Nontelomeric TRF2-REST interaction modulates neuronal gene silencing and fate of tumor and stem cells. Curr. Biol. 18: 1489-1494.
56. Zhang Y, Dang C, Ma Q, Shimahara Y. 2005. Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer. Oncol. Rep. 14:161-171.